The elusive HER3, known to drive aggressive cancers, may finally be toppled by once-abandoned antibody drugs.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Trans-activating mutations of the pseudokinase ERBB3
Oncogene Open Access 28 May 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. HER3-addicted tumors: how biotechs are closing in. Nat Biotechnol 40, 1157–1159 (2022). https://doi.org/10.1038/s41587-022-01425-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01425-9
This article is cited by
-
Trans-activating mutations of the pseudokinase ERBB3
Oncogene (2024)